What is Etrolizumab? Quick Facts about New IBD Treatment

What is Etrolizumab? Quick Facts about New IBD Treatment

Ulcerative colitis (UC) patients are gaining access to the new UC treatment etrolizumab through clinical trials—and the results are looking promising.

Quick facts about Etrolizumab

Developed by: Roche; Genentech Research and Early Development

Conditions: Ulcerative colitis and Crohn’s disease. The majority of early clinical trial data is on ulcerative colitis.

Drug type: Monoclonal antibody, integrin inhibitor. Etrolizumab is in the same general category as IBD therapies such as vedolizumab and natalizumab (along
with other drugs ending in -mab). All are monoclonal antibodies and integrin inhibitors; the difference lies in which integrins they target.

Administration: Injection (one injection per month)

How It Works: Etrolizumab is a monoclonal antibody that targets certain integrins (receptors in the cell membranes). Integrins play a vital role in the pathology of many diseases and are involved in the processes of inflammation, wound healing, and more. Etrolizumab inhibit several lymphocyte integrins (β7 subunit of integrins α4β7 and αEβ7) which, in turn, modifies the body’s immune inflammatory response.

Find Your Treatment

See what treatments are right for you by answering a couple questions.

Have you had diarrhea within the past week?

Yes No

Etrolizumab Research

Crohn’s and ulcerative colitis patients have become familiar with dominant anti-TNF brand names such as Humira, Remicade, and Cimzia. While these IBD medications have helped many patients, some patients don’t have a response to these anti-TNF therapies—or become unresponsive over time. Etrolizumab is one of several new IBD medications that are being developed with the aim of achieving greater efficacy, lower costs, and fewer side effects for patients.

Richard Scheller, Head of Genentech Research and Early Development, commented on preliminary clinical data for Etrolizumab in May of 2018: “Etrolizumab, in a convenient subcutaneous monthly dosing, could significantly reduce the signs and symptoms of this debilitating disease.”

Data from the Phase 2 EUCALYPTUS trial found that 21% of patients taking 100mg of Etrolizumab had achieved remission by week 10, compared to 0% remission in the placebo group. Ongoing research on Etrolizumab is examining the effects of Etrolizumab in patients who have never tried anti-TNF therapy, as well as patients who have tried anti-TNF therapy with limited success.

Etrolizumab Clinical Trials for UC

Etrolizumab is currently in Phase 3 clinical trials for ulcerative colitis, with researchers and physicians testing the new UC treatment on real patients who have UC.

In Phase 3 trials, the data has already shown the treatment to be safe, and researchers are examining its therapeutic effects before approval and release on the market.

Signing up for IBD Clinical Trials: Etrolizumab

Clinical trials evaluate the effects of new therapies on patients to assess efficacy, safety, and dosing, among other metrics.

Participants in IBD clinical trials have often tried a handful of IBD treatment options already. Participating in a trial provides them with early access to the latest treatments as well as face-to-face time with IBD specialists who are dedicated to improving the available IBD therapies.

Clinical Trials across North America

At Discover Therapies, we connect Crohn’s and colitis patients with clinical trials across North America.

Contrary to what many people believe, clinical trials are often held at clinics—the same type of clinic you’d visit for an appointment with your gastroenterologist.

Currently, the University of Chicago Medicine and the GI Research Institute in Vancouver, BC are recruiting for several Etrolizumab trials.

Patients can gain access to Crohn's and ulcerative colitis clinical trials by taking a short eligibility quiz at Discover Therapies.

References
Lee, H. S., Park, S.-K., & Park, D. I. (2018). Novel treatments for inflammatory bowel disease. The Korean Journal of Internal Medicine, 33(1), 20–27. http://doi.org/10.3904/kjim.2017.393
Millard, M., Odde, S., & Neamati, N. (2011). Integrin Targeted Therapeutics. Theranostics, 1, 154–188. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086618/
(2018) The University of Chicago Medical Center. IBD Research and Clinical Trials. Retrieved from http://www.uchospitals.edu/specialties/gi/ibd/research.html

Support

Sign up now and speak to a research coordinator